Even though we did not observe any statistically significant difference in TTP with respect to different pAkt Thr308 or pAkt Ser473 localization, there was, once again, an unexpected trend to longer TTP in patients with activated Akt in both the cytoplasm and nucleus (pAkt-n+c) compared to tumours with pAkt detected in the cytoplasm only (pAkt-c): pAkt Thr308-n+c vs. pAkt Thr308-c, 10.2 vs. 8.3 months; pAkt Ser473-n+c vs. pAkt Ser473-c, 9.4 vs. 8.1 months, none of these results were, however, statistically significant. The gene discussed is AKT1; the disease is neoplasm.